Foss, Francine
Mayo Clinic
Hematology and Stem Cell Transplantation, Yale University School of Medicine, New Haven, CT.
Citations 2
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Olsen, Elise A. , Whittaker, Sean , Willemze, Rein , Pinter‐Brown, Lauren , Foss, Francine M. , Schwartz, Lawrence , Guitart, Joan , Zic, John A., Wood, Gary S. , Ai, Wei , Gru, Alejandro A. , Guenova, Emmanuella , Hodak, Emmilia , Hoppe, Richard T. , Lechowicz, Mary Jo , Ortiz‐Romero, Pablo L. , Papadavid, Evangelia , Pittelkow, Mark R. , Prince, H. Miles , Sanches, José Antônio , Sugaya, Makoto , Vermeer, Maarten H. , Knobler, Robert , Stadler, Rudolf , Scarisbrick, Julia , Foss, Francine , Kim, Youn H , Gru, Alejandro , Guenova, Emmanuella , Ortiz-Romero, Pablo , Prince, H Miles , Sanches, Jose Antonio , Sugaya, Makoto , Vermeer, Maarten , Zain, Jasmine , Knobler, Robert , Stadler, Rudolf , Scarisbrick, Julia , Hoppe, Richard T , Geskin, Larisa J. , Horwitz, Sarah McCue , Duvic, Madeleine , Ai, Wei, Girardi, Michael , Kempf, Werner , Kim, Ellen , Quaglino, Pietro , Bagot, Martine
Blood | November 11, 2021 | Volume: 140 | Issue: 5 | Pages: 419-437
Abstract The number of patients with primary cutaneous lymphoma (PCL) relative to other non-Hodgkin lymphomas (NHLs) is small and the number of subtypes large. Although clinical trial guidelines have been published for mycosis fungoides/Sézary syndrome, the most common type of PCL, none exist for the other PCLs. In addition, staging of the PCLs has been evolving based on new data on potential prognostic factors, diagnosis, and assessment methods of both skin and extracutaneous disease and a desire to align the latter with the Lugano guidelines for all NHLs. The International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous LymphomaConsortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC) now propose updated staging and guidelines for the study design, assessment, endpoints, and response criteria in clinical trials for all the PCLs in alignment with that of the Lugano guidelines. These recommendations provide standardized methodology that should facilitate planning and regulatory approval of new treatments for these lymphomas worldwide, encourage cooperative investigator-initiated trials, and help to assess the comparative efficacy of therapeutic agents tested across sites and studies.
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902
Foss, Francine M. , Wang, Victoria , Luger, Selina M. , Miller, Kenneth B., Stadtmauer, Edward A. , Avigan, David , Gascoyne, Randall D., Wagner, Henry, Strair, Roger , Sprague, Kellie , Litzow, Mark R. , Tallman, Martin S. , Horning, Sandra J., Foss, Francine , Jegede, Opeyemi A. , Whiteside, Theresa L , Arber, Daniel A. , Hogan, William J. , Lazarus, Hillard M.
Transfusion | July 12, 2020 | Volume: 60 | Issue: 8 | Pages: 1867-1872
BackgroundExtracorporeal photopheresis (ECP) is an immunomodulatory cellular therapy which has been shown to induce a tolerogenic state in patients with acute and chronic graft‐vs‐host disease. ECOG‐ACRIN explored the activity of ECP as a part of a reduced intensity conditioning regimen in two multicenter trials in patients with MDS (E1902) and lymphomas (E1402). While both studies closed before completing accrual, we report results in 23 patients (17 MDS and 6 lymphoma).Study Design and MethodsPatients received 2 days of ECP followed by pentostatin 4 mg/m2 /day for two consecutive days, followed by 600 cGy of total body irradiation prior to stem cell infusion. Immunosuppression for aGVHD was infusional cyclosporine A or tacrolimus and methotrexate on day +1, +3, with mycophenolate mofetil starting on day 100 for chronic GVHD prophylaxis.ResultsAll patients engrafted, with median time to neutrophil and platelet engraftment of 15‐18 days and 10‐18 days respectively. Grade 3 or 4 aGVHD occurred in 13% and chronic extensive GVHD in 30%.ConclusionsThese studies demonstrate that ECP/pentostatin/TBI is well tolerated and associated with adequate engraftment of neutrophils and platelets in patients with lymphomas and MDS.